Key Highlights:
- Zydus Lifesciences has launched its semaglutide injection in India under three brands, Semaglyn, Mashema, and Alterme, following patent expiry. The therapy is approved by DCGI for both type 2 diabetes and obesity, positioning Zydus among the latest entrants in India’s growing GLP-1 market
- Setting itself apart, Zydus is offering a reusable multi-dose pen that allows patients to select and administer different dose strengths from a single device, eliminating the need for multiple single-dose pens during titration. The semaglutide will be available in a 15 mg/3 mL cartridge and manufactured at its Biotech Park in Ahmedabad, with an average monthly therapy cost of ~₹2,200
- With diabetes and obesity emerging as major health challenges in India, Zydus is aligning its launch with rising demand for GLP-1 therapies. As per estimates, ~8.9 crore adults in India live with diabetes (~10.5% prevalence), while obesity rates continue to climb sharply across genders, highlighting the need for accessible, long-term treatment options in the country
Implications:
Zydus is differentiating in a crowded GLP‑1 space with a single reusable multi‑dose pen and 15 mg/3 mL cartridge, simplifying titration and potentially reducing overall therapy cost versus multiple single‑dose pens.
With an average monthly cost around ₹2,200 and in‑house manufacturing at its Ahmedabad Biotech Park, the company is targeting scale in both diabetes and obesity, aligning with rapidly growing GLP‑1 demand in a country with ~8.9 crore adults living with diabetes and rising obesity burden.
Source: Zydus | Image: Zydus
